{"id":25570,"date":"2026-06-24T17:30:00","date_gmt":"2026-06-24T15:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=40b9c8213461e6061a7587cc33d60fdb"},"modified":"2026-06-24T17:30:00","modified_gmt":"2026-06-24T15:30:00","slug":"bioivt-names-sean-downing-phd-to-scientific-advisory-board","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=25570","title":{"rendered":"BioIVT Names Sean Downing, PhD, to Scientific Advisory Board"},"content":{"rendered":"

\nIndustry veteran will strengthen BioIVT's scientific strategy by advancing the quality, characterization, and applicability of biospecimens to meet emerging research needs<\/i><\/p>

WOODBURY, N.Y.--(BUSINESS WIRE)--BioIVT<\/a>, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it has appointed Sean Downing, PhD, to its Scientific Advisory Board to continue advancing the quality, characterization, and applicability of biospecimens. In addition, his appointment will enhance the integration of BioIVT\u2019s richly annotated clinical data, multiomic insights, and biomarker expertise to enable more predictive and translationally relevant research.<\/p><\/a><\/a>

\n\u201cWe are thrilled to welcome Sean to BioIVT\u2019s Scientific Advisory Board, where his expertise will help advance innovation and optimization across the preclinical development process,\u201d said Courtney Noah, Vice President of Scientific Affairs at BioIVT. \u201cSean\u2019s deep experience in translational science and biomarker strategy matched with regulated diagnostics will help BioIVT anticipate emerging scientific and clinical needs and will provide perspective on how sponsors are evolving their biomarker, assay, and sample strategy requirements.\u201d<\/p>

\nSean\u2019s background includes holding biomarker and translational leadership roles in precision medicine across diagnostics, CROs, and biopharma in R&D and clinical development. He has led global biomarker strategy, CLIA\/CAP lab operations, and cross-functional teams advancing medical devices, trials, and regulatory submissions, and most recently, served as the Vice President of Scientific Affairs for ICON plc.<\/p>

\n\u201cI look forward to bringing a translational perspective, connecting BioIVT's capabilities with the biomarker needs of drug and diagnostics developers,\" said Downing. \u201cBy identifying high-value opportunities for internal data generation, we can strengthen BioIVT\u2019s scientific credibility, further differentiate its offerings, and accelerate innovation that supports more predictive and clinically relevant research.\u201d<\/p>

\nFor more information on how BioIVT is elevating science and moving research forward, please visit here<\/a>.<\/p>

\nAbout BioIVT<\/b><\/p>

\nBioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE\u00ae<\/sup>. For more information, please visit www.bioivt.com<\/a> or follow us on LinkedIn<\/a>.<\/p> Contacts<\/b>

\nBioIVT Contact:<\/b> Charlie Chungu, Vice President of Marketing, cchungu@bioivt.com<\/a>Media Contact: <\/b>Alex Connelly, PAN, 401-486-7437, BioIVT@pancomm.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Industry veteran will strengthen BioIVT’s scientific strategy by advancing the quality, characterization, and applicability of biospecimens to meet emerging research needsWOODBURY, N.Y.–(BUSINESS WIRE)–BioIVT, the leading biospecimen solutions provi…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-25570","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25570"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25570\/revisions"}],"predecessor-version":[{"id":25571,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25570\/revisions\/25571"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}